Life Sciences BC Launches Labor Market Study on Jobs and Skills Needed for BC’s Growing Life Sciences Sector
Vancouver, British Columbia–(BUSINESS WIRE)–A new Labor Market Information (LMI) study that will help better understand the jobs and skills employers are looking for is underway for BC’s vibrant life sciences sector. The project is led by Life Sciences British Columbia (LSBC) with funding provided through the Canada-British Columbia Labor Market Development Agreement under the Sector Labor Market Partnerships program with the Ministry of Higher Education and Vocational Training.
The study will result in an updated profile of the life sciences workforce in British Columbia; five-year labor supply and demand forecasts; vocational training evaluation; gender-based analysis plus (GBA+) data; and recommendations for sector-led strategies. The results will benefit organizations in the sector and those who work with them, including post-secondary institutions and government, as they seek to address workforce challenges and make investment decisions.
“British Columbia’s life sciences sector is innovative, growing and playing an important role in the province’s economic recovery and growth, while meeting healthcare needs,” said Anne Kang. , Minister of Higher Education and Vocational Training. “This project will support this growth by engaging with people in the sector to understand labor market needs and develop a skills training assessment and map of available and necessary training for current and future workforce needs. work.”
“BC is home to the fastest growing life sciences sector in the country, with BC companies earning international acclaim for their work on treatments, technologies and vaccines,” said Ravi Kahlon, Minister of Jobs, Economic Recovery and Innovation. “This study will help support the growth of this important sector as we take the next steps to strengthen our province’s economic future and build a StrongerBC.”
“BC’s life sciences sector has been on a growth trajectory for several years, and our response to the COVID-19 pandemic has sparked global interest in our innovation and capabilities,” said Wendy Hurlburt. , President and CEO of Life Sciences BC. “The LMI project is a comprehensive tool that will draw on extensive research and consultation to create an understanding of current and future workforce dynamics and labor market needs under different scenarios. This data will support our sector in its ability to plan and sustain growth.
The study is expected to last 11 months with feedback and oversight provided by a strong governance committee made up of members from industry, academia and government. Stakeholder engagement is a critical success factor and will include focus groups, surveys, interviews as well as collaboration with BioTalent Canada.
Life Sciences British Columbia (LSBC) is a not-for-profit industry association that advocates, supports and represents BC’s life sciences community provincially, nationally and globally. Through numerous initiatives, the LSBC plays an important role in facilitating investments and collaborations, raising awareness of British Columbia as a center of excellence for life sciences, and shaping the trajectory of the sector.
The Sectoral Labor Market Partnerships program helps industry and employers understand and respond to changes in the labor market, and provides funding to organizations in an economic sector, region or population, to develop projects that help meet workforce challenges.
The labor market sector partnership between the province and industry will be led by Life Sciences BC with funding support from the Ministry of Advanced Education and Skills Training.
British Columbia is home to the fastest growing life sciences sector in Canada with more than 2,000 companies employing 18,000 British Columbians working on innovations and research to improve healthcare delivery around the world .
Life sciences products made in British Columbia include rapid diagnostic tests for diseases such as HIV/AIDS, Hepatitis C and Ebola virus; therapeutic proteins for the treatment of cancer, autoimmune and inflammatory diseases; and the first FDA-approved oral drug for the treatment of adult patients with active lupus nephritis. British Columbia scientists and businesses have played a key role in the development of the COVID-19 vaccine.
British Columbia is home to three of Canada’s largest biotech companies, STEMCELL Technologies, AbCellera Biologics and Aurinia Pharmaceuticals; and Canada’s largest medical device company, Starfish Medical.